TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma

Post time 1 hour(s) ago

journal：Journal of Clinical Oncology

Authors：Pascal Hammel; Jean-Philippe Metges; Teresa Macarulla Mercade; Rocio Garcia-Carbonero; Olivier Bouché; Fabienne Portales; Roberto A. Pazo Cid; Laurent Mineur; Antonio Cubillo Gracian; Isabelle Trouilloud; Rosine Guimbaud; David Tougeron; Juan Jose Reina; Jaime Feliu; Tamara Sauri; Christos Fountzilas; Thierry Lecomte; Yann Molin; Mariano Ponz-Sarvise; Frederic Forget; Rossana Berardi; Eric Van Cutsem; Fabio Gelsomino; Christophe Tournigand; Bruno Bockorny; Jean Baptiste Bachet; Miguel Marin Vera; Pieter-Jan Cuyle; Harpreet Wasan; Marcus Noel; Jean-Luc Van Laethem; Richard Kay; Hagop Youssoufian; Iman El-Hariry; Manuel Hidalgo

Published date：2025-12-10

DOI：10.1200/jco-25-00872

PDF link：https://ascopubs.org/doi/pdfdirect/10.1200/JCO-25-00872

Article link：https://doi.org/10.1200/jco-25-00872

Article Source：American Society of Clinical Oncology (ASCO)。

Remark：

[Other] TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma Copy

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma